Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer
- Wellcome Trust Sanger Institute, United Kingdom
- University of Cambridge, United Kingdom
- Cambridge University Hospitals NHS Foundation Trust, United Kingdom
- University of New South Wales, Australia
- National Cancer Centre, Singapore
- Dana-Farber Cancer Institute, United States
- Institute of Cancer Research, Sutton, United Kingdom
- University of Oxford, United Kingdom
- MD Anderson Cancer Center, United States
- University of Nottingham, United Kingdom
- National Institute of Health, United States
- University of North Carolina, United States
- University of Toronto, Canada
- University of Liverpool, United Kingdom
- University of East Anglia, United Kingdom
- University of Tampere, Finland
- Johns Hopkins University, United States
- Royal National Orthopaedic Hospital, United Kingdom
- Newcastle University, United Kingdom
Abstract
Recent sequencing studies have extensively explored the somatic alterations present in the nuclear genomes of cancers. Although mitochondria control energy metabolism and apoptosis, the origins and impact of cancer-associated mutations in mtDNA are unclear. Here, we analysed somatic alterations in mtDNA from 1,675 tumors. We identified 1,907 somatic substitutions, which exhibited dramatic replicative strand bias, predominantly C>T and A>G on the mitochondrial heavy strand. This strand-asymmetric signature differs from those found in nuclear cancer genomes but matches the inferred germline process shaping primate mtDNA sequence content. Numbers of mtDNA mutations showed considerable heterogeneity across tumor types. Missense mutations were selectively neutral and often gradually drifted towards homoplasmy over time. In contrast, mutations resulting in protein truncation undergo negative selection and were almost exclusively heteroplasmic. Our findings indicate that the endogenous mutational mechanism has far greater impact than any other external mutagens in mitochondria, and is fundamentally linked to mtDNA replication.
Article and author information
Author details
Reviewing Editor
- Todd Golub, Broad Institute, United States
Ethics
Human subjects: We obtained informed consent and consent to publish from participants enrolled in this study.Ethical approval references:Genome Analysis of myeloid and lymphoid malignancies (10/H0306/40)Genomic Analysis of Mesothelioma (11/EE/0444)Myeloid and lymphoid cancer genome analysis (07/S1402/90)The Treatment of Down Syndrome Children with Acute Myeloid Leukemia and Myelodysplastic Syndrome(AAML0431)CLL (chronic lymphocytic leukaemia) genome analysis (07/Q0104/3)CGP-Exome sequencing of Down syndrome associated acute myeloid leukemia samples (IRB 13-010133)Cancer Genome Project - Global approaches to characterising the molecular basis of paediatric ependymoma (05/MRE04/70)PREDICT-Cohort (09/H0801/96)ICGC Prostate (Evaluation of biomarkers in urological diseases) (LREC 03/018)ICGC Prostate (779) (Prostate Complex CRUK Sample Cohort) (MREC/01/4/061)ICGC Prostate (Tissue collection at radical prostatectomy) (CRE-2011.373)Somatic molecular genetics of human cancers, melanoma and myeloma (Dana Farber Cancer Institute)(08/H0308/303)Breast Cancer Genome Analysis for the International Cancer Genome Consortium Working Group (09/H0306/36)Genome analysis of tumours of the bone (09/H0308/165)
Version history
- Received: March 28, 2014
- Accepted: September 26, 2014
- Accepted Manuscript published: October 1, 2014 (version 1)
- Version of Record published: November 4, 2014 (version 2)
Copyright
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Metrics
-
- 12,808
- views
-
- 2,006
- downloads
-
- 295
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer
eLife 3:e02935.
https://doi.org/10.7554/eLife.02935
Further reading
-
- Genetics and Genomics
PARP-1 is central to transcriptional regulation under both normal and stress conditions, with the governing mechanisms yet to be fully understood. Our biochemical and ChIP-seq-based analyses showed that PARP-1 binds specifically to active histone marks, particularly H4K20me1. We found that H4K20me1 plays a critical role in facilitating PARP-1 binding and the regulation of PARP-1-dependent loci during both development and heat shock stress. Here, we report that the sole H4K20 mono-methylase, pr-set7, and parp-1 Drosophila mutants undergo developmental arrest. RNA-seq analysis showed an absolute correlation between PR-SET7- and PARP-1-dependent loci expression, confirming co-regulation during developmental phases. PARP-1 and PR-SET7 are both essential for activating hsp70 and other heat shock genes during heat stress, with a notable increase of H4K20me1 at their gene body. Mutating pr-set7 disrupts monomethylation of H4K20 along heat shock loci and abolish PARP-1 binding there. These data strongly suggest that H4 monomethylation is a key triggering point in PARP-1 dependent processes in chromatin.
-
- Cancer Biology
- Genetics and Genomics
Enhancers are critical for regulating tissue-specific gene expression, and genetic variants within enhancer regions have been suggested to contribute to various cancer-related processes, including therapeutic resistance. However, the precise mechanisms remain elusive. Using a well-defined drug-gene pair, we identified an enhancer region for dihydropyrimidine dehydrogenase (DPD, DPYD gene) expression that is relevant to the metabolism of the anti-cancer drug 5-fluorouracil (5-FU). Using reporter systems, CRISPR genome-edited cell models, and human liver specimens, we demonstrated in vitro and vivo that genotype status for the common germline variant (rs4294451; 27% global minor allele frequency) located within this novel enhancer controls DPYD transcription and alters resistance to 5-FU. The variant genotype increases recruitment of the transcription factor CEBPB to the enhancer and alters the level of direct interactions between the enhancer and DPYD promoter. Our data provide insight into the regulatory mechanisms controlling sensitivity and resistance to 5-FU.
